Objectives

Acute myeloid leukemia (AML) is still challenging in predicting the prognosis due to its high heterogeneity. Molecular aberrations and abnormalities play a significant prognostic role in AML patients. Our aim of the study was to investigate the prognostic role of TNFRSF4 gene expression in AML patients and its potential effect on treatment protocols.

Methods

Bone marrow mononuclear cells were analyzed for TNFRSF4 expression by real-time quantitative PCR as well as of FLT3/ITD and NPM1 mutations in 80 newly diagnosed AML patients and 80 control subjects.

Results

TNFRSF4 was significantly overexpressed in the AML patients (p < 0.001). TNFRSF4 expression was associated with unfavorable clinical outcomes including treatment response, relapse free survival, and overall survival. On multivariate testing, TNFRSF4 high expression proved to be an independent prognostic marker for clinical remission and relapse free survival but not overall survival.

Conclusion

TNFRSF4 expression was revealed as an unfavorable prognostic marker and might be a target for immunotherapy in the future.

中文翻译：

---

肿瘤坏死因子受体超家族成员4（TNFRSF4）基因表达在急性髓系白血病诊断及预后中的作用

目标

急性髓性白血病 (AML) 由于其高度异质性，在预测预后方面仍然具有挑战性。分子畸变和异常在 AML 患者中起着重要的预后作用。我们的研究目的是研究 TNFRSF4 基因表达在 AML 患者中的预后作用及其对治疗方案的潜在影响。

方法

通过实时定量 PCR 分析骨髓单个核细胞的 TNFRSF4 表达以及 80 名新诊断的 AML 患者和 80 名对照受试者的 FLT3/ITD 和 NPM1 突变。

结果

TNFRSF4 在 AML 患者中显着过表达（p < 0.001）。TNFRSF4 表达与不利的临床结果相关，包括治疗反应、无复发生存期和总生存期。在多变量测试中，TNFRSF4 高表达被证明是临床缓解和无复发生存但不是总生存的独立预后标志物。

结论

TNFRSF4 表达被揭示为不利的预后标志物，并可能成为未来免疫治疗的目标。